Back to results
US 2023/0146125 A1Published application
Forms and compositions of inhibitors of jak2
AssigneeAjax Therapeutics, Inc.
InventorsCraig E. Masse, Jeremy R. Greenwood, Jiayi Xu, Sayan Mondal, Phani Ghanakota
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds and compositions thereof which are useful as inhibitors of JAK2 and which exhibit desirable characteristics for the same.
Claims34
A solid form of Compound 1:
- wherein the solid form is a hydrate and is characterized in that it has three or more peaks in its X-ray powder diffraction (XRPD) pattern selected from those at angles (degrees 2 theta±0.2) of 7.32, 11.15, 13.99, 16.58, 18.95, 21.68, 23.56, 25.23, and 26.60.
2-3. (canceled)
(canceled)
A solid form of Compound 1:
- wherein the solid form is anhydrous and is characterized in that it has three or more peaks in its X-ray powder diffraction (XRPD) pattern selected from those at angles (degrees 2 theta±0.2) of 8.08, 11.76, 15.73, 17.31, 19.32, 19.54, 23.13, 25.90, and 27.31.
8-14. (canceled)
A process for preparing a solid form of Compound 1:
- wherein the process comprises steps of stirring Compound 2:
- in water, and then removing the solvent to provide the solid form of Compound 1.
17-18. (canceled)
A solid form of Compound 1:
- wherein the solid form is selected from the group consisting of a Compound 1 salt or co-crystal form of benzenesulfonic acid, camphorsulfonic acid (e.g., (1R)-(−)-10-camphorsulfonic acid), 1,2-ethanedisulfonic acid, ethansulfonic acid, hydrobromic acid, hydrochloric acid, methanesulfonic acid, phosphoric acid, and sulfuric acid.
(canceled)
35-38. (canceled)
40-47. (canceled)
52-55. (canceled)
Dependencies are inferred from the claim text.